LivingGLP1
Study S000904

A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter, 24 Week Study Assessing the Safety and Efficacy of Lixisenatide in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Diabetes Treatment Regimen

Included trial: extracted dataClinicalTrials.gov record

Registration

Registration
NCT01798706
Acronym
GetGoal-O
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE3
Masking
QUADRUPLE
Status
COMPLETED
Enrollment
350
Start
2013-06
Primary completion
2015-02
Lead sponsor
Sanofi
Conditions
Type 2 Diabetes
Interventions
DRUG:Lixisenatide (AVE0010); DRUG:Placebo; DRUG:Antidiabetic background therapy
Results posted
TRUE
Secondary identifiers
EUDRACT_NUMBER:2012-003292-19; OTHER:U1111-1132-9156

Registered primary outcomes

  • Absolute Change in HbA1c From Baseline to Week 24 [Baseline, Week 24]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0010237Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.
Natale P, The Cochrane database of systematic reviews
2025Systematic reviewPMID 39963952DOIcites ClinicalTrials.gov:NCT01798706; registry reference DERIVED:39963952
R0024428Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial.
Meneilly GS, Diabetes care
2017Randomized trialPMID 28188240DOIcites ClinicalTrials.gov:NCT01798706; registry reference RESULT:28188240
R0048873Lixisenatide Therapy in Older Patients with Type 2 Diabetes Inadequately Controlled on Their Current Anti-Diabetic Treatment: The GetGoal-O Study (NCT01798706)
Graydon S. Meneilly, Canadian Journal of Diabetes
2016OtherDOIcites ClinicalTrials.gov:NCT01798706